[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"menopause-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:menopause-syndrome":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100619929","exercise-as-medicine-a-non-pharmacological-approach-to-menopausal-symptoms-100619929",false,"NCT07351006","Exercise as Medicine: A Non-Pharmacological Approach to Menopausal Symptoms","Inclusion Criteria:\n\n* Biological female sex\n* Age 45-55 years\n* Experiencing menopausal symptoms, defined as irregular or altered menstruation plus at least one of the following:\n* Hot flashes or sweating\n* Sleep problems\n* Mood swings or depression\n* Dry mucous membranes\n* Recurrent urinary tract infections or overactive bladder\n* Joint pain\n* Decreased libido\n* Weight gain\n\nExclusion Criteria:\n\n* Have taken medication or natural remedies for menopausal symptoms in the past 2 months\n* Menopause due to illness or surgical intervention\n* Medical conditions that contraindicate participation in the exercise intervention\n* Engaged in physical activity for ≥150 minutes per week, including ≥ 75 minutes at high intensity","FEMALE","45 Years","55 Years",{"count":19,"type":20},45,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this clinical trial is to evaluate the effects of different forms of physical exercise in women experiencing menopausal symptoms. Specifically, the project investigates the effects of: (1) strength training on women's perceived menopausal symptoms; (2) dance-based exercise on women's perceived menopausal symptoms; and (3) adherence to structured, digital home-based exercise programs.\n\nThe following research questions will be addressed within the framework of the project:\n\nDoes regular strength training reduce women's perceived menopausal symptoms?\n\nTo what extent does strength training influence menopausal symptoms and sleep quality in women?\n\nWhat is the level of adherence to a digital, home-based strength training program among women with menopausal symptoms?\n\nDoes regular dance-based physical activity reduce women's perceived menopausal symptoms?\n\nTo what extent does dance-based physical activity influence menopausal symptoms and sleep quality in women?\n\nWhat is the level of adherence to a digital, home-based dance exercise program among women with menopausal symptoms?\n\nWhich exercise protocol-strength training or dance-based exercise-has the greatest effect on perceived menopausal symptoms?\n\nThe researchers will compare a digital, home-based strength training program with a digital, home-based dance exercise program, as well as with a control group, to determine which type of exercise has the greatest effect on menopausal symptoms and sleep quality.\n\nParticipants will:\n\nPerform either dance-based exercise or strength training for 8 weeks, three times per week, following a structured program of approximately 30 minutes per session, or participate as part of the control group.\n\nComplete validated questionnaires assessing menopausal health, including somatic, psychological, and sexual symptoms, as well as perceived quality of life and sleep quality, both before and after the intervention.\n\nMaintain a training diary to monitor adherence and progression, including increases in training intensity",[26,27],"Menopause Syndrome","Sleep Disturbance","RECRUITING","2026-01-09",{"date":31,"type":32},"2026-01-20","ACTUAL",{"date":34,"type":32},"2025-11-01",{"date":36,"type":20},"2026-12",{"name":38,"class":39},"Linnaeus University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":15,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":40},"100589848","magnesium-l-threonate-improves-menopausal-symptoms-100589848","NCT06959745","Magnesium-L-Threonate Improves Menopausal Symptoms","Magnesium-L-Threonate Improves Menopausal Symptoms: A Single-center, Single-blind, Randomized, Placebo-Controlled Pilot Study","Inclusion Criteria:\n\n1. Women aged 40-60 years;\n2. Postmenopausal status or in the late menopausal transition stage. 3. Postmenopausal status is defined as: natural menopause with no menstruation in the past 12 months. The late menopausal transition stage will be defined as: amenorrhea for at least 60 days within the past 12 months;\n\n4\\. MRS score ≥15 points based on symptoms in the past 1 month; 5. Willing to complete the required follow-up visits during the trial period. 6. Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. History of bilateral oophorectomy or hysterectomy;\n2. Current or past use of magnesium L-threonate preparations or similar nutrient formulations within the last 3 months;\n3. Definite history of gastrointestinal diseases that may affect the absorption of the investigational drug;\n4. Definite history of liver diseases that may affect the metabolism of the investigational drug;\n5. Definite history of kidney diseases that may affect the excretion of the investigational drug, with serum creatinine levels \\> 2 mg\u002FdL (88.4 μmol\u002FL);\n6. Current or recent use of hormone replacement therapy: vaginal or transdermal estrogen within the past 4 weeks; oral estrogen or progesterone within the past 8 weeks; intrauterine progesterone therapy within the past 8 weeks; progesterone implants or estrogen injection therapy within the past 3 months; estrogen pellet therapy or progesterone injection therapy within the past 6 months; or intention to use these medications during the intervention period;\n7. Current or past use of medications such as clonidine, methyldopa, gabapentin, pregabalin, and selective serotonin or norepinephrine reuptake inhibitors (SSRIs\u002FSNRIs) within the past 1 month, or intention to use these medications during the intervention period;\n8. Current or past use of phosphodiesterase inhibitor medications within the past 1 month, or intention to use these medications during the intervention period;\n9. Autoimmune diseases requiring medication, current or past treatment with glucocorticoids, antirheumatic drugs, or biologics within the past 6 months, or intention to use these medications during the intervention period;\n10. Depression or anxiety requiring medication, current or past use of antidepressants within the past 3 months, or intention to use these medications or treatments during the intervention period;\n11. Current or past use of hypnotic medications such as diazepam or triazolam within the past 2 weeks, or intention to use these medications during the intervention period;\n12. Osteoarthritis, osteoporosis, or other musculoskeletal diseases requiring medication;\n13. Known allergy to magnesium L-threonate;\n14. History of malignancy, or life expectancy less than 1 year;\n15. Major surgery within the past 6 months, or intention to undergo surgery during the intervention period, including but not limited to cardiac surgery or joint replacement;\n16. Currently pregnant, having given birth within the past 3 months, planning pregnancy during the study period, or unwilling to use conventional barrier contraception or abstain from sexual activity to prevent pregnancy if not fully menopausal;\n17. Currently breastfeeding, having breastfed within the past 3 months, or planning to breastfeed during the study period;\n18. Unable or unwilling to provide informed consent, complete questionnaires, or attend study visits;\n19. Participation in other interventional studies;\n20. Other conditions judged by the investigator as unsuitable for trial participation. These conditions may make potential participants highly unlikely to adhere to the study protocol, including plans to relocate, substance abuse, severe psychiatric issues, or severe dementia.",true,"40 Years","60 Years",{"count":52,"type":20},50,[23],"This trial has a randomized, single-blind, single-center, parallel-controlled design, with participant screening and trial implementation conducted at Guangdong Provincial People's Hospital. The study evaluate the efficacy of oral magnesium L-threonate supplementation on improving menopausal symptoms and quality of life among peri\u002Fpost-menopausal women.\n\nThis trial aims to explore whether oral magnesium L-threonate supplementation could alleviate menopausal syndromes.\n\nParticipants will randomly assigned to conduct oral magnesium L-threonate supplementation or placebo for 8 weeks. Face-to-face and internet follow up will be conducted once per 2 weeks.",[26,56],"Magnesium",[58],"menopause syndrome","NOT_YET_RECRUITING","2025-05-04",{"date":62,"type":32},"2025-05-07",{"date":64,"type":20},"2025-05-15",{"date":66,"type":20},"2025-12-30",{"name":68,"class":39},"Guangdong Provincial People's Hospital"]